Hims & Hers Health has undeniably captured market attention and investor enthusiasm, fueled by a successful Super Bowl ad campaign and its strategic entry into the high-demand GLP-1 weight loss ...

Shares in telehealth business Hims & Hers Health (HIMS) dropped over 6% today after reports that it and peers are marketing ...

The debate over the ad highlights the ongoing tension between branded pharmaceutical companies and providers of lower-priced generic drugs. Compounded drugs, like those sold by Hims and Hers, do ...

The “Check before you inject” ad specifically calls out compounded medications, which is the type that Hims & Hers manufactures and is not FDA approved. Novo Nordisk blasted its telehealth ...

It took an eagle eye to spot that disclaimer on the Hims & Hers ad, however, as it was printed in small white font on a gray background. The ad also did not follow a practice required for FDA ...

Hims & Hers is under fire over an ad for its weight loss offerings that's slated to run during the Super Bowl on Sunday. Two U.S. senators expressed concern over an "upcoming advertisement" that ...

Earlier in February, Hims & Hers Health rallied as it was set to debut its controversial Super Bowl ad, where it positioned itself as the “affordable, doctor-trusted, formulated in the US ...

Apostrophe, a Bay Area telehealth company focused on skin care, shut down after almost four years under the Hims & Hers ...

Telehealth company Hims & Hers has had enough—and is putting its money where its mouth is in the form of its first Super Bowl ad, called “Sick of the System.” The minute-long commercial is ...

Hims & Hers saw a massive YTD surge, but FDA news led to a pullback. Find out why HIMS stock is still undervalued and why acquisitions boost its outlook.